Didanosine Ddi

Drug Index

Didanosine (ddI, DDI), sold under the brand name Videx, is a medication used to treat HIV/AIDS.[1] It is used in combination with other medications as part of highly active antiretroviral therapy (HAART). It is of the reverse-transcriptase inhibitor class. Didanosine was first described in 1975 and approved for use in the United States in 1991.[2] Contents 1 Adverse effects 2 Drug interactions 3 Resistance 4 Mechanism of action 5 Pharmacokinetics 6 History 7 ...

Didanosine, ddI

Didanosine (ddI, DDI), sold under the brand name Videx, is a medication used to treat HIV/AIDS.[1] It is used in combination with other medications as part of highly active antiretroviral therapy (HAART). It is of the reverse-transcriptase inhibitor class. Didanosine was first described in 1975 and approved for use in the United States in 1991.[2] Contents 1 Adverse effects 2 Drug interactions 3 Resistance 4 Mechanism of action 5 Pharmacokinetics 6 History 7 ...

Didanosine, ddI

Didanosine (ddI, DDI), sold under the brand name Videx, is a medication used to treat HIV/AIDS.[1] It is used in combination with other medications as part of highly active antiretroviral therapy (HAART). It is of the reverse-transcriptase inhibitor class. Didanosine was first described in 1975 and approved for use in the United States in 1991.[2] Contents 1 Adverse effects 2 Drug interactions 3 Resistance 4 Mechanism of action 5 Pharmacokinetics 6 History 7 ...

Didanosine, ddI

Didanosine (ddI, DDI), sold under the brand name Videx, is a medication used to treat HIV/AIDS.[1] It is used in combination with other medications as part of highly active antiretroviral therapy (HAART). It is of the reverse-transcriptase inhibitor class. Didanosine was first described in 1975 and approved for use in the United States in 1991.[2] Contents 1 Adverse effects 2 Drug interactions 3 Resistance 4 Mechanism of action 5 Pharmacokinetics 6 History 7 ...